AUTHORS
Syed Mahamad, MSc, Jacqueline Arnold2, Bianca Clerici3, Emily Marie Harris, MD4, Rick Ikesaka, MD, MSc, BSc5, Hayley Merkeley, MD FRCPC6, Kristine Matusiak, MBBS, FRCPC7, Nicole Relke, MD, BSc8, Ishac Nazy, PhD9, Donald Arnold, MD10
AFFILIATIONS
1 McMaster University, Hamilton, Ontario, Canada
2 McMaster University, Hamilton, Ontario, Canada
3 ASST Santi Paolo e Carlo, Milan, Italy, University of Milan, Milan, Italy
4 Boston Children's Hospital, Boston, United States, Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
5 University of British Columbia, Vancouver, British Columbia, Canada
6 University of British Columbia, Vancouver, British Columbia, Canada
7 McMaster University, Hamilton, Ontario, Canada
8 Canadian Blood Services, Toronto, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
9 McMaster University, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
10 McMaster University, Hamilton, Ontario, Canada, McMaster University, Hamilton, Ontario, Canada
ABSTRACT
Introduction
Thrombocytopenia is a common reason for outpatient hematology consultation, but establishing the underlying cause can be challenging. As part of a real-world validation study for a new clinical prediction tool, the clinical diagnosis of thrombocytopenia among patients referred to a hematology clinic for evaluation was adjudicated independently by a blinded central committee. Here we report the results of the adjudication process.
Methods
Adjudication of the clinical diagnosis was conducted as part of a multicenter retrospective cohort study of consecutive patients with thrombocytopenia from 9 hematology clinics in Canada. Eligible patients were adults with a platelet count <100 x109/L who were referred to the hematology clinic for evaluation of the thrombocytopenia. The final clinical diagnosis was established by the treating hematologist as per standard practice using all available clinical and laboratory information at the end of follow-up. Diagnostic categories were: immune thrombocytopenia (ITP), non-immune thrombocytopenia (non-ITP), mild thrombocytopenia, a separate platelet disorder, or unresolved. Patients were adjudicated if the final clinical diagnosis was considered ambiguous because it was 1) unresolved; 2) changed between visits; 3) occurred during pregnancy; or 4) contained a discrepancy in the data. In addition, a random sample of 10% of patients who did not have an ambiguous diagnosis was adjudicated to verify the clinical diagnosis and estimate agreement between the clinical and adjudicated diagnoses (Cohen's kappa). The primary objective was to determine the proportion of patients whose diagnosis was resolved, and the proportion with a major change in diagnosis (e.g., from ITP to non-ITP, or vice versa) after adjudication.
The adjudication committee consisted of 5 hematologists with experience in ITP diagnosis and management. Adjudicators were calibrated to the diagnostic categories using examples that were discussed as a group. Two adjudicators independently reviewed their assigned patients’ information and provided their assessment of the cause of the thrombocytopenia blinded to the clinical diagnosis. Disagreements among pairs of adjudicators were discussed with the full committee and resolved by consensus.
Results
We included 689 patients with thrombocytopenia in this study. Of those, 198 (28.7%) were adjudicated because the final clinical diagnosis was ambiguous: 81 (40.9%) were unresolved; 75 (37.9%) changed between visits; 45 (22.7%) had thrombocytopenia during pregnancy; and 15 (7.6%) had a discrepancy in the data (18 patients had more than one reason for adjudication). The median age of patients with an ambiguous diagnosis was 68 years [interquartile range (IQR) 45–80], and 109 (55.1%) were female.
After adjudication, the diagnosis was resolved in 64/81 (79.0%) patients: 30 (46.9%) were reclassified as ITP, and 34 (53.1%) as non-ITP. After adjudication, a major change in diagnosis occurred for 8 [4.0%; from ITP to non-ITP (n=4), and from non-ITP to ITP (n=4)]. Adjudication resulted in a change in the subcategory of primary or secondary ITP for 16 (8.1%) patients; a change in the subcategory of non-ITP for 6 (3.0%) patients; a change from mild thrombocytopenia to ITP for 2 (1.0%) patients; and a change from mild thrombocytopenia to non-ITP for 1 (0.5%) patient.
Among the 48 randomly selected patients, there was excellent agreement between the final clinical diagnosis and the adjudicated diagnosis (44/48, 91.7%; Cohen's kappa 0.84, 95% CI 0.68–0.96).
Conclusions
In a real-world cohort of hematology outpatients referred for evaluation of thrombocytopenia, approximately 30% of patients had a clinical diagnosis that was ambiguous. Among patients with an unresolved clinical diagnosis, adjudication resolved nearly 80% of diagnoses. Among all patients with an ambiguous diagnosis, adjudication resulted in a major diagnostic change in 4.0%. These findings highlight the uncertainty in the diagnosis of thrombocytopenia and the value of central adjudication.
DISCLOSURES
Syed Mahamad, MSc: Sobi - Research Funding